Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance
Open Access
- 1 June 2026
- journal article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 139
Abstract
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Despite surgery and adjuvant imatinib for high-risk cases, recurrence remains high, often due to resistance from secondary kinase mutations. Imatinib is known to influence lipid metabolism in GIST and chronic myeloid leukemia (CML). This study evaluates metabolic trends in recurrent GIST post-resection to determine whether these biomarkers can signal resistance or early recurrence. Methods: This retrospective cohort study utilized de-identified data from the TriNetX database, comprising over 200 million patients across 172 healthcare systems in 18 countries. We examined total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), TG/HDL ratio, low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c, body mass index (BMI), and thyroid-stimulating hormone (TSH) in 36 patients with recurrent GIST on imatinib. Results: Thirty-six patients were included in this study. Patients underwent resection an average of 25.9 months before recurrence. Total cholesterol increased significantly (R=0.92, P=0.03), while LDL-C showed a similar increasing trend (R=0.87, P=0.050). HDL-C decreased significantly between pre- and post-recurrence periods (P=0.03). BMI differed between pre- and post-recurrence periods (P=0.047). TG showed a strong positive correlation (R=0.93, PConclusions: Patients with GIST recurrence demonstrated worsening metabolic profiles preceding recurrence—rising total cholesterol, LDL-C, TG, and BMI with declining HDL-C and TSH. Given imatinib’s usual lipid-lowering effects, reversal of this pattern may reflect emerging resistance. These metabolic biomarkers could serve as early, non-invasive indicators of recurrence and guide timely intervention.Keywords
This publication has 20 references indexed in Scilit:
- Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumorsTherapeutic Advances in Medical Oncology, 2012
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)Oncology Reports, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib.2005
- Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification studyInternational Journal of Cancer, 2005
- Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene MutationClinical Cancer Research, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to TreatmentJournal of Clinical Oncology, 2004
- A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal TumorsCancer Research, 2004